Transcriptomic profiling corroborates these findings, showing that elevated YAP1 and WWTR1 mRNA levels in tumor specimens correlate with advanced clinical stage, higher metastatic risk, and shorter overall survival (Moya and Halder, 2019) (Hermann et al., 2021); immunohistochemistry further confirms that nuclear YAP positivity is enriched in late-stage, chemoresistant cases (Hermann et al., 2021). Here, WWTR1 is linked to neoplasm.